Spondyloarthritis & psoriatic arthritis
The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort
Authors' conclusion
A cumulative 60-month DRR of secukinumab of 57.0% in patients with PsA was retrieved. The presence of cardiometabolic multimorbidity could be associated with an improved DRR of secukinumab, whereas obesity did not affect this feature in our cohort. Previous bDMARDs, concomitant csDMARDs, and different drug dosages could not influence the DRR of secukinumab over time.
Study context
- Population
- Patients with PsA attending the recruiting centres, January 2016–June 2022
- Participants
- 207 patients
- Outcome
- Drug retention rate (DRR) of secukinumab
- Follow-up
- 60 months
Methodological detailsreal-life, multicentre, prospectively followed-up patients
- Real-life
- Multicentre
- Prospectively followed-up patients
Main finding
As reported in the abstract
DRR of secukinumab
Secukinumab
57.0%
- Mean time of administration
- 21.5±17.1 months
Observational data: associations, not effects.
Further findings
Influence of patient characteristics and treatment on drug retention rate (DRR)
- Male gender, age ≥65 years, disease duration ≥5 years and ≥10 years did not influence the DRR
- Presence of comorbidities (any concomitant disorder) did not affect the DRR
- Cardiometabolic multimorbidity: trend toward a better DRR
- High blood pressure, dyslipidaemia and type 2 diabetes: trend toward an improved DRR
- Obesity did not influence the DRR
- Different dosages, previous bDMARDs and concomitant csDMARDs did not influence the DRR
Original publication
The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort. Clin Exp Rheumatol. Published 3 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →